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Abstract
Composite bone cements were prepared with bioactive glasses (MgO–SiO2–3CaO Æ P2O5) of different reactivities. The matrix of these
so-called hydrophilic, partially degradable and bioactive cements was composed of a starch/cellulose acetate blend and poly(2-hydroxy-
ethyl methacrylate). The addition of 30 wt.% of glasses to this system made them bioactive in acellular medium: a dense apatite layer
formed on the surface after 7 days of immersion in simulated body fluid. This was demonstrated both by microscopic and infrared spec-
troscopic techniques. The composition of the glass and, consequently, its structure was found to have important effects on the rate of the
apatite formation. The combination of reactivity obtained by one formulation with the hydrophilic and degradable character of these
cements makes them a very promising alternative to conventional acrylic bone cements, by allowing a better stabilization of the implant
and a stronger adhesion to the bone.
! 2006 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Keywords: Acellular bioactivity; Bioactive glasses; Acrylic cements; Degradable polymer; Hydrophilic
1. Introduction
The main cause of failure of cemented arthroplasties is
the aseptic loosening of the prosthesis, which usually
occurs at the cement–bone interface (considered to be the
weakest link in the implant system [1]) and requires a sec-
ond surgery for replacement of the whole system. A variety
of causes have been proposed for this problem [2–4]: ther-
mal necrosis of bone due to the high exothermic tempera-
ture of cement polymerization, chemical necrosis of bone
due to the release of unreacted methylmethacrylate
(MMA), shrinkage during polymerization, weakness of
the cement (and the interfaces) when compared with the
prosthesis, and the bone and stress shielding of the bone
due to improper transfer of load. The determining factor,
however, is the lack of strong interaction between the
cement and the bone, since the only source of adhesive
strength is the interdigitation of the cement with the bone,
without any apparent chemical lock [5].
Increasing the interfacial strength between bone and
cement is essential to achieving good performance of the
prosthesis. The most studied method to obtain such
improvement is by incorporating bioactive fillers in bone
cements, creating a surface-bioactive material, i.e. a mate-
rial that is able to establish a direct bond to bone [6].
Although bone particles [7,8] and growth hormones [9,10]
have been used for this, bioactive glasses [11] or glass–
ceramics [12,13] and hydroxylapatite (HA) [14–16] are the
most promising and studied fillers. Besides imparting bio-
active character to the cements, these fillers additionally
improved compressive, tensile and flexural properties.
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However, two main problems exist with these formulations
[6,17]: (i) in some cases, the amount of filler that can be
included without deleterious effects on the mechanical or
handling properties is so small that the increase in bioactiv-
ity is not likely to be very large; (ii) the glass or ceramic fill-
ers tend to make poly(methylmethacrylate) (PMMA), an
already brittle material, even more brittle. One way to take
advantage of the bioactive potential and mechanical rein-
forcement of such fillers is by changing the matrix formu-
lation, creating a cement with higher ductility and lower
modulus. Such cement allows greater axial movement of
the stem relative to the bone, increasing proximal load
transfer, and acts as a load spreader, resulting in a more
even load transmission between prosthesis and bone [6].
As brittleness is not a major concern, high amounts of filler
can be added, improving mechanical properties and
imparting a strong bioactive behavior to the cement.
Hydrophilic, degradable and bioactive cements
(HDBCs) were developed with this aim in mind [2,18].
They contain an hydrogel-forming monomer (2-hydroxy-
ethyl methacrylate, HEMA) in the liquid component of
the typical bone cement formulation, partially substituted
for MMA in order to adjust the mechanical and the
swelling properties of the system. Therefore, the key
characteristics of hydrophobic, acrylic cements, such as
fast polymerization rate, injectability and high mechani-
cal properties are maintained; and the advantages of
hydrogels – good compatibility with body fluids and tis-
sues, improved release behavior of drugs, easier surface
reactivity [19], etc. – are added. After swelling, the ductil-
ity and energy to fracture are greatly improved, reaching
a maximum 7 days after immersion [20]. These hydro-
philic bone cements also incorporate a starch-based blend
that can degrade in the body and has already been stud-
ied for a range of biomedical applications such as
scaffolds for tissue engineering [21,22], systems for drug-
delivery [23,24], hydrogels [25,23], and bone replacement
and regeneration applications [26,27]. These cements
could be made bioactive by the addition of bioactive fill-
ers such as HA, as has been previously shown [28]. The
bioactive filler additionally increases the mechanical prop-
erties of the dry formulations [11]. However, in previous
experiments we used a combination of low-reactivity
glass with a monomer (acrylic acid, AA) that had an
inhibitory effect on the apatite growth. Due to this fact,
AA was later replaced by HEMA [29], which lead to
an increase on the surface reactivity, for the same kind
of glass.
The aim of the present work was to study the in vitro
bioactive behavior of HDBCs containing HEMA. The fill-
ers were, as previously stated, surface-reactive glasses of
the 3CaO Æ P2O5–SiO2–MgO system. However, this time
two glasses of higher reactivity were chosen [30], in order
to minimize the problems found in the previous formula-
tions. The formulations were immersed in simulated body
fluid (SBF) and their surface was extensively characterized
with spectroscopic and microscopic techniques.
2. Materials and methods
Specimens were prepared by adding the solid component
to the liquid component. The solid was constituted by a
commercial corn starch/cellulose acetate 50/50 wt.% blend
(SCA, Novamont, Italy) and one of two bioactive glasses
(Mg31 and Mg36). The glasses were produced by the
authors and their preparation is described in Ref. [30]. Their
composition, particle sizes and surface area are shown in
Table 1. These glasses have been selected in a compositional
series, studied in a previous work [30], where the SiO2/MgO
ratio is kept constant and correponds to the higher MgO
contents tested in that work. Particle size was determined
by laser scattering analysis using a Coulter LS100 particle
size analyser; the values reported correspond to the mean
values of particle size. The specific surface area was mea-
sured in a Micrometrics-Gemini 2370 V5, by nitrogen
adsorption using the Brunauer, Emmett and Teller (BET)
isotherm. The polymer particles were smaller than
125 lm, determined by sieving the powder and collecting
the fraction smaller than this size. The liquid was consti-
tuted by 2-hydroxyethyl methacrylate (HEMA, Fluka, Ger-
many), which was used as received. Benzoyl peroxide
powder (BPO, Merck, Germany) was used as the polymer-
ization initiator at a molar concentration of 0.01 with
respect to the monomer amount. Dimethyl-p-toluidine
(DMT, Aldrich, Germany) was used as the activator of
the initiator, at a molar concentration of 0.67 with respect
to the BPO amount. The solid/liquid ratio employed was
65/35 (by mass) and the concentration of the glass was fixed
at 32.5 wt.% of the total mass (i.e. 50 wt.% of the solid com-
ponent). The two formulations were named as BC31 and
BC36, according to the glass used.
The preparation of specimens for subsequent tests was
carried out following the traditional method. The activator
DMT was dissolved in the liquid phase. The initiator of
free radical polymerization reaction was added to the solid
phase. Both phases were mixed and stirred by hand until
the mixture became paste-like with a high viscosity; the
mass was then placed into a poly(tetrafluoroethylene)
(PTFE) mold to allow it to cure.
The in vitro bioactive behavior of the prepared bone
cement formulations was studied over a period of 30 days
in acellular medium. Prismatic specimens (20 mm ·
4 mm · 1.5 mm) were immersed immediately after prepara-
tion in 13 ml of a SBF (142.0 mM Na+, 5.0 mM K+,
2.5 mM Ca2+, 1.5 mM Mg2+, 147.8 mM Cl!, 4.2 mM
HCO!3 , 1.0 mM HPO
2þ
4 , 0.5 mM SO
2!
4 ). The specimens
were removed at intervals of 1, 3, 4, 7, 9, 14 and 30 days;
they were taken out of the solution, rinsed with distilled
water and dried at room temperature. After drying, the
specimens were stored at 23 "C and 55% humidity. Ali-
quots of solution (2 ml) were taken at the same test times
from the containers to measure the concentration of the
elements Ca, P, Si and Mg by inductively coupled plasma
(ICP) emission spectroscopy using a Jobin-Yvon JY70 Plus
spectrometer.
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Surface modifications of the materials were studied by
scanning electron microscopy (SEM) on a Leica Cam-
bridge S360 microscope. When high magnifications were
used, a Hitachi S-4100 microscope was employed. This
microscope had an associated energy dispersive spectros-
copy (EDS) equipment with semi-quantitative calibration;
this allowed the calculation of the relative amounts of spe-
cific elements on the layer. All specimens were carbon cov-
ered before SEM/EDS analysis.
The specimen’s surface was also analyzed with a Fou-
rier-transformed infrared (FTIR) spectrophotometer with
an attenuated total reflectance (ATR) module. The equip-
ment employed was a Perkin–Elmer 1600 series, with a
spectral resolution of 4 cm!1. Non-sintered hydroxyapatite
(HA), with a particle size in the range 4.1–9.0 lm, was
obtained from Plasma Biotal, UK, and used only for com-
parative purpose in infrared spectroscopy.
3. Results
SEM micrographs (Fig. 1(a–d)) showed that precipi-
tates were present on the surface of BC31 after 4 days
of immersion in SBF. After 1 day, the surface changed
considerably (as compared to the non-immersed speci-
mens), but no deposits were visible even at high-
magnifications. A dense and thick layer was present after
9 days of immersion. Fig. 1(e) shows a high-magnification
micrograph of a specimen after 4 days of immersion; the
starter agglomerates, prior to layer formation, can be
clearly seen in greater detail (white arrow). Fig. 1(f) and
1(g) shows high-magnification micrographs of specimens
immersed for 7 days in the SBF. A needle-like ‘‘cauli-
flower’’ morphology is clearly visible. As discussed later,
this morphology is typical of apatite formation.
A comparison between both samples is showed in Fig. 2.
The surface of BC36 (Fig. 2(a)) was covered by sparse pre-
cipitates and a few small agglomerates. The surface of
BC31 (Fig. 2(b)), on the other hand, was covered by a
dense layer.
Fig. 3 shows a comparison of the EDS spectra of formu-
lation BC31 before and after immersion in SBF. Fig. 3(a)
shows the presence of all elements that constitute the glass
(Mg, Si, P and Ca). After 7 days of immersion, only Ca
and P are detected; the other elements (plus Cl from the
solution) are present in residual amounts on the surface.
Fig. 3(c) shows a spectra of one of the precipitates displayed
in Fig. 1(e), proving that these deposits are formed from Ca
and P and are, therefore, the initiators of the apatite forma-
tion. Based on these spectra, the atomic ratios of Ca/P were
calculated for each immersion period and are displayed in
Table 2; the ratio initially decreased, but started to increase
after the build-up of the first precipitates.
Fig. 4 shows the ICP curves for both formulations. The
profiles are similar: the concentration of Ca and P initially
increased, then started to decrease after 3 days of immer-
sion; on the other hand, Mg and Si concentrations
increased continuously. For all elements shown there
(except for Si), the concentration in solution was higher
for the formulation containing Mg31 than for the one con-
taining Mg36.
FTIR was also used to characterize the surface of the
specimens. Fig. 5(a) presents the spectra of BC31 and its
three main constituents. The influence of each substance/
material is visible in the spectrum of the bone cement: a
large and intense band centered at 1050 cm-1, due to the
stretching of Si–O bonds of the glass; an intense band cen-
tered at 1750 cm!1, due to the stretching vibrations of ester
(C@O) linkages present in both HEMA and SCA; a weak
band at ~2950 cm!1 due to the stretching of alkyd bonds;
and a large and a weak band centered at 3400 cm!1 due
to the stretching vibrations of OH groups present in
HEMA, SCA and the water molecules incorporated in
them. Fig. 5(b) shows the spectra of BC31 after 1 and 14
days of immersion, as well as a spectrum of non-sintered
HA for comparison.
4. Discussion
The first step in the evaluation of the bioactivity of any
biomaterial is the study of its in vitro reactivity and ability
to form a calcium phosphate layer when immersed in SBF.
Materials that are successful in this preliminary in vitro
test, i.e. which develop the layer, are considered to bond
directly with bone [31]. Typically, polymers (such as bone
cements) do not possess this property, and need to be
loaded with bioactive fillers in order to do so. However,
as we have previously shown, this condition is necessary,
but not sufficient [11]: depending on the monomer used
in the bone cement formulation, even high-reactivity
glasses can only nucleate small Ca–P agglomerates, with-
out forming a layer. Therefore, a different monomer
(HEMA) was later employed, and the calcium phosphate
layer was, in this case, formed.
In this work, we employed an HEMA cement com-
pounded with two bioactive glasses, more reactive than
the one previously used [11]. Both glasses imparted acellu-
lar bioactivity to the formulations, although Mg31 was
more reactive than Mg36, as shown in Fig. 2: even after
14 days in SBF, BC36 presented only small agglomerates
of Ca–P on its surface, while a dense layer had formed
Table 1
Molar composition and properties of the used glasses
Glass SiO2 (%) CaO (%) P2O5 (%) MgO (%) Particle size (lm) Specific surface area (m
2/g)
Mg31 25.37 32.62 10.87 31.14 11.3 0.284
Mg36 29.37 25.96 8.65 36.02 10.2 0.233
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Fig. 1. SEMmicrographs of the surface of specimens of BC31 immersed in SBF for 0 (a), 1 (b), 4 (c) and 9 (d) days. High-magnification SEMmicrographs
of the surface of specimens of BC31 immersed in SBF for 4 (e) and 7 (f, g) days.
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on the surface of BC31. This observation correlated with
the ICP curves shown in Fig. 4: after the initial period of
increase in the concentration of Ca2+ and PO3!4 in SBF
(corresponding to the elements Ca and P in the figure),
the decrease in the concentration was more intense for
the solution corresponding to BC31 (for both elements),
meaning that a greater amount of calcium and phospho-
rous was being consumed from the solution due to their
precipitation as a layer. In the first day after immersion,
higher amounts of both Ca2+ and PO3!4 were released from
BC31 to the solution, which might be expected due to the
higher amounts of these elements in the composition of
BC31 as compared to BC36. These results are in agreement
with those obtained with the same glasses in bulk form [30]:
in that study, the layer formed on the surface of a bulk
specimen of Mg31 was thicker than that formed on the sur-
face of Mg36; moreover, the concentration of Ca2+ and
PO3!4 started to decrease on the first day for Mg31 but only
on the second day for Mg36. Similarly, in the case of our
cements, the concentration of Ca2+ started to decrease on
the first day for BC31, but only after the third day for
BC36. This fact may be related to the composition of the
two glasses. Mg31 contains less silica than Mg36 and a
higher amount of network modifiers. Continuous leaching
of calcium and magnesium to the solution may be respon-
sible for the disruption of the main silica network, thus
promoting a faster and more extensive dissolution of silica.
Additionally, this glass (Mg31) contains more CaO and
P2O5, which, when dissolved, contribute for saturating
the solution and expediting the apatite formation.
The ICP results indicate that precipitation of Ca–P
should start on the first day (for BC31), which was not
observed microscopically (Fig. 1(b)). As outlined previ-
ously, this was probably due to the magnifications that
could be attained with both microscopes. Only at 4 days
were the precipitates large enough to be observed. These
aggregates, as shown in the spectra of Fig. 3(c), were
formed mainly of Ca and P, consumed from the solution.
For all immersion times in SBF the ionic concentration
of Ca2+ is always higher than the initial one, for zero time,
and the ionic concentration of PO3!4 slightly decreases.
Since SEM micrographs and EDS analysis clearly showed
the presence of a Ca–P layer, it becomes obvious that
Ca2+ and PO3!4 from the solution have been previously
provided by the glass itself, which is highly soluble in the
plasmatic solution. The observed apatite layer is thus the
result of a complex reprecipitation process. After 4 days,
Si and Mg are still present in relevant amounts. As the time
of immersion increases, the precipitates originate a dense
layer of Ca–P, and the amounts of other elements become
residual. After long immersion times, it seems that some Cl
from the SBF is incorporated in the layer. For similar time
periods, the EDS spectrum of BC36 (data not shown)
shows much more intense peaks for Si and Mg, proving
that the layer was thinner and not totally covering the sur-
face, allowing the appearance of the peaks coming from the
glass.
Due to this difference between the reactivity of the two
glasses, only BC31 was chosen for further characterization.
This included FTIR spectroscopy and semi-quantitative
EDS analysis. The evolution of the spectra with immersion
time confirms the previous discussion: at 1 day, no differ-
ence could be seen in the curves and the spectrum remained
identical to that of the original sample; however, after 14
days the bands disappeared and only a strong and large
band at 1000 cm!1 is seen. The comparison with a spec-
trum of non-sintered HA shows the similarity between
both spectra, and makes it possible to assign the observed
band to the phosphate groups present in HA or other cal-
cium phosphate minerals.
The evolution of the Ca/P ratio shown in Table 2 indi-
cates that, initially, a different calcium phosphate phase is
formed, which is either amorphous or crystalline. As the
precipitates grew to form a layer, the ratio also grew,
approaching that of HA. After 1 week, the value stabilized
at Ca/P = 1.59. The atomic Ca/P ratio is 1.67 in stoichiom-
etric HA; however in bone, as well as in layers precipitated
on bioactive materials, this value is usually lower due to the
presence of carbonates, forming hydroxycarbonate apatite
(HCA) [32].
These results, together, demonstrated that the developed
composites induce the nucleation and growth of an apatite
layer when immersed in SBF. This is a strong indication
that these materials should exhibit high bone-bonding
Fig. 2. SEM micrographs of the surface of specimen of BC36 (a) and BC31 (b) after 14 days of immersion in SBF.
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potential in vivo. But, due to the other characteristics of
these HDBCs, this property will be potentiated. In other
papers, we have shown that the hydrophilicity of these
materials allows them to exert compressive forces on the
constraining walls (bone and prosthesis) from the first
moments of water uptake [33]; this increases the contact
area between cement and bone and the interfacial shear
strength, which is beneficial for implant stabilization and
for the bioactivity itself. We have also demonstrated that
degradation of these cements can be controlled by a variety
of methods [34]; this generates a network of interconnected
pores and channels which can be filled by bone that is
induced to grow by the bioactive behavior we report here.
In that way, the final situation of the system would be that
of a bone-reinforced cement, possessing much improved
properties compared to commercial cements or even to
other bioactive formulations. The bioactive glass, besides
Fig. 3. EDS spectra of the surface layer of BC31 before (a) and after (b) 7 days of immersion in SBF. (c) EDS spectrum of the precipitate indicated in
Fig. 1(e).
Table 2
Evolution of Ca/P atomic ratio as function of immersion time of
formulation BC31 in SBF, as determined by EDS analysis
Time of immersion (days) Ca/P (atomic ratio)
0 1.82
4 1.38
7 1.59
14 1.59
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inducing bioactivity, also helps to increase the mechanical
properties of the cements and their doughing time [11].
The next steps in this research will be (i) to perform simul-
taneous tests of degradation and bioactivity, to confirm the
hypothesis above, and, if this proves successful, (ii) also to
perform in vivo tests to assess the compatibility of the
cements with the surrounding tissues. Moreover, glass
Mg36 will be heat treated to produce a glass–ceramic,
which would improve mechanical properties and promote
better adhesion of the layer to the cement’s surface [35],
although this might lead to a decrease in its bioactivity.
5. Conclusion
We have developed novel HDBCs that contain degrad-
able starch-based blends and bioactive glasses. The compo-
sition of the glass was an important parameter controlling
the kinetics of apatite growth on the surface of the cement,
and formulations with high-reactivity could be obtained by
using the proper glass. These cements are a promising alter-
native to conventional bone cements, due to the excellent
combination of mechanical, curing, degradation and bioac-
tive properties. The results of the in vitro tests reported
herein allow one to predict a positive behavior in future
in vivo studies. If the bioactivity is confirmed in animal
and clinical tests, it should promote bone formation on
the surface of the cement in contact with bone and, if cou-
pled with an adequate degradation profile, would also
allow bone ingrowth inside the pores of the partially
degraded cement.
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